Shanghai Fosun Pharmaceutical Gains NMPA Approval for XH-S003 in PNH Treatment
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced receiving clinical trial...
Drug
Trinomab Biotech Launches Xintituo for Tetanus Treatment in Zhuhai
China-based Trinomab Biotech Co., Ltd announced the first delivery of its antitetanus toxin monoclonal antibody...
Tasly Pharma’s NR-20201 Receives NMPA Approval for Acute Ischemic Stroke Trial
China-based Tasly Pharma Co., Ltd (SHA: 600535) announced receiving approval from the National Medical Products...
Jiangsu Aidea’s AD108 Receives NMPA Approval for Acute Ischemic Stroke
China’s Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) announced receiving clinical approval from the National...
China Medical System’s CMS-D003 Receives NMPA Approval for Clinical Study in oHCM
China Medical System Holdings (CMS; HKG: 0867) announced receiving approval from the National Medical Products...
Zai Lab Submits TIVDAK BLA to China’s NMPA for Cervical Cancer Treatment
Zai Lab Limited (NASDAQ: ZLAB, HKG: 9688) announced that a Biological License Application (BLA) for...
Haisco Pharmaceutical’s HSK44459 Receives NMPA Approval for Psoriasis and Atopic Dermatitis Trials
China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) announced receiving approval from the National Medical...
Arvinas and Pfizer Announce Positive Phase III Results for Vepdegestrant in ER+/HER2- Breast Cancer
Partners Arvinas, Inc. (NASDAQ: ARVN) and Pfizer Inc. (NYSE: PFE) announced positive topline results from...
CDE Releases 91st Batch of Reference Preparations for Generic Drug Evaluation
China’s Center for Drug Evaluation (CDE) has released the 91st batch of reference preparations for...
Jiuzhitang’s Stem Cell Therapy for Autism Receives NMPA Clinical Trial Approval
China-based Jiuzhitang Co. Ltd (SHE: 000989) announced receiving clinical trial approval from the National Medical...
Novartis’ Cosentyx Approved by NMPA for Moderate to Severe Hidradenitis Suppurativa
Swiss giant Novartis’ (NYSE: NVS) Cosentyx (secukinumab) has secured another indication approval from China’s National...
Biogen Initiates TRANSCEND Study for Felzartamab in Late AMR Kidney Transplant Patients
US-based Biogen Inc. (NASDAQ: BIIB) announced the initiation of the TRANSCEND study, a global Phase...
AIM Vaccine Co. Ltd Announces Market Filing for Innovative Serum-Free Rabies Vaccine
China-based AIM Vaccine Co., Ltd (HKG: 6660) announced plans to file for market approval for...
Ascletis Pharma’s ASC47 Shows Positive Results in Phase Ib Study for Weight Loss
China-based Ascletis Pharma Inc. (HKG: 1672) announced positive topline results from a Phase Ib clinical...
AstraZeneca’s Imfinzi Approved by NMPA for Early-Stage NSCLC Treatment
UK-based giant AstraZeneca (NASDAQ: AZN) received approval from China’s National Medical Products Administration (NMPA) for...
Sichuan Kelun-Biotech’s Sacituzumab Tirumotecan Wins New NMPA Approval for NSCLC
China-based Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced receiving another indication approval from the...
Huadong Medicine Seeks Regular Approval for Elahere in Ovarian Cancer Treatment
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its application for converting conditional to...
Lundbeck’s Amlenetug Receives Orphan Drug Designation in Japan for Multiple System Atrophy
Denmark-based pharmaceutical company Lundbeck A/S (OTCMKTS: HLUBF) announced receiving Orphan Drug Designation (ODD) from Japan’s...
Jiangsu Hengrui Pharmaceuticals Receives NMPA Approval for HRS-4029 in Acute Ischemic Stroke
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced receiving clinical trial approval from the...
InnoCare Pharma Presents Positive Phase II Results of ICP-488 in Psoriasis at AAD Meeting
China-based InnoCare Pharma (HKG: 9969, SHA: 688428) announced the oral presentation of results from the...